Elicio Therapeutics, Inc.
ELTX
$8.05
$0.091.13%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 19.96% | 25.66% | -160.59% | 38.88% | -32.16% |
| Total Depreciation and Amortization | -8.85% | 5.17% | -1.02% | 1.03% | 1.40% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -8.19% | -86.65% | 391.24% | -250.02% | 448.36% |
| Change in Net Operating Assets | -109.61% | 109.14% | 38.30% | 146.13% | -69.55% |
| Cash from Operations | -15.73% | -20.21% | 18.53% | 26.35% | -22.51% |
| Capital Expenditure | -- | -- | 100.00% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -100.00% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 100.00% | -1,500.00% | -- |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 4,449.78% | -98.04% | 3,563.29% | -97.13% | 57.51% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -- | -- | -- |
| Cash from Financing | 4,449.78% | -99.26% | 9,632.28% | -97.13% | 57.46% |
| Foreign Exchange rate Adjustments | 14.81% | -25.00% | 187.80% | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 102.81% | -136.29% | 370.45% | -694.06% | 62.16% |